Novo Nordisk A/S Class B

Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B's next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B has 28.93B shares outstanding.

As of June 30, 2026, Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B maintains a current ratio of 0.87, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 63.33, indicating elevated leverage, while an interest coverage ratio of 273.09 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B posted a return on equity (ROE) of 59.82, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 33.40 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 21.62, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 37.19, useful for judging operating efficiency across full business cycles. The company generates approximately 712,588.12 in revenue per employee across its workforce of 70,671.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.31 indicates how many times Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B recorded 4.94B in income tax expense. That works out to an effective tax rate of 21.72, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 22.74B, leaving 17.80B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Over the twelve months ended June 30, 2026, Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B generated 50.36B in revenue and converted that into 17.80B in net income, yielding earnings per share of 0.78. EBITDA reached 24.76B, while operating income came in at 21.72B.

As of June 30, 2026, Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B holds 6.88B in cash and equivalents against 21.42B in total debt, resulting in a net debt position of 14.62B. Total book value stands at 33.83B, with working capital of -4.65B providing operational flexibility.

Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B produced 20.16B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -12.85B in capital expenditures, free cash flow totaled 7.31B - equivalent to 0.32 per share.

Over the twelve months ended June 30, 2026, Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B posted a gross margin of 80.65, reflecting its pricing power and cost economics. The operating margin of 43.13 and net profit margin of 35.35 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B paid dividends of 0.35 per share. The dividend payout ratio of 44.64 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.